Editas Medicine to Participate in Upcoming Investor Conferences

EDIT 11.06.2024

Full Press ReleaseSEC FilingsOur EDIT Tweets

About Gravity Analytica

Recent News

  • 01.15.2025 - 43rd Annual J.P. Morgan Healthcare Conference
  • 01.13.2025 - Editas Medicine Highlights New In Vivo Preclinical Proof of Concept Data, Anticipated 2025 Key Milestones, and Three-year Strategic Priorities
  • 01.06.2025 - Editas Medicine to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Recent Filings

  • 01.13.2025 - EX-99.1 EX-99.1
  • 01.13.2025 - 8-K Current report
PDF Version

CAMBRIDGE, Mass.,Nov. 06, 2024(GLOBE NEWSWIRE) --Editas Medicine, Inc.(Nasdaq: EDIT), a clinical-stage gene editing company, today announced that management will participate in the following upcoming investor conferences in November and December:

  • Guggenheim’sInaugural Healthcare Innovation ConferenceFormat: Fireside ChatDate:Tuesday, November 12Time:4:00 p.m. ETLocation:Boston, MA
  • Stifel 2024 Healthcare ConferenceFormat: Fireside ChatDate:Tuesday, November 19Time:1:50 p.m. ETLocation:New York, NY
  • 7th AnnualEvercore ISI HealthCONx ConferenceFormat: Fireside ChatDate:Tuesday, December 3Time:1:20 p.m. ETLocation:Coral Gables, FL

To access the live webcasts of Editas Medicine’s presentations, please visit the “Investors” section of the Company’s website atwww.editasmedicine.com. An archived replay will be available for approximately 30 days following each event.

AboutEditas MedicineAs a clinical-stage gene editing company,Editas Medicineis focused on translating the power and potential of the CRISPR/Cas12a and CRISPR/Cas9 genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world.Editas Medicineaims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases.Editas Medicineis the exclusive licensee of Broad Institute’s Cas12a patent estate andBroad Instituteand Harvard University’s Cas9 patent estates for human medicines. For the latest information and scientific presentations, please visitwww.editasmedicine.com.

Media and Investor Contact:Cristi Barnett(617) 401-0113cristi.barnett@editasmed.com

Primary Logo

Source: Editas Medicine, Inc.

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com